Eli Lilly and Company (LLY)
Eli Lilly and Company is an American multinational pharmaceutical company. It was founded in 1876 and is headquartered in Indianapolis, Indiana. The company develops, manufactures, and markets a wide range of pharmaceutical products, including prescription drugs and vaccines, for various medical conditions.
Company Info
US5324571083
532457108
Jan 13, 1978
Highlights
$715.22B
$9.57
78.73
0.69
$40.86B
$33.33B
$12.51B
$558.01 - $970.92
$992.18
0.78%
2.21
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Eli Lilly and Company, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Eli Lilly and Company had a return of 29.16% year-to-date (YTD) and 26.52% in the last 12 months. Over the past 10 years, Eli Lilly and Company had an annualized return of 29.83%, outperforming the S&P 500 benchmark which had an annualized return of 11.21%.
LLY
29.16%
-17.05%
-7.08%
26.52%
47.10%
29.83%
^GSPC (Benchmark)
25.15%
2.97%
12.53%
31.00%
13.95%
11.21%
Monthly Returns
The table below presents the monthly returns of LLY, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 10.75% | 16.94% | 3.22% | 0.40% | 5.20% | 10.37% | -11.17% | 19.53% | -7.72% | -6.34% | 29.16% | ||
| 2023 | -5.93% | -9.28% | 10.35% | 15.27% | 8.77% | 9.20% | -3.08% | 22.18% | -3.08% | 3.13% | 6.90% | -1.37% | 60.91% |
| 2022 | -11.16% | 2.28% | 14.57% | 2.01% | 7.66% | 3.44% | 1.68% | -8.33% | 7.34% | 11.98% | 2.76% | -1.41% | 34.24% |
| 2021 | 23.18% | -1.07% | -8.82% | -2.17% | 9.77% | 14.91% | 6.09% | 6.42% | -10.55% | 10.26% | -2.32% | 11.36% | 66.07% |
| 2020 | 6.25% | -9.21% | 9.98% | 11.48% | -0.63% | 7.34% | -8.46% | -0.78% | -0.25% | -11.86% | 12.21% | 15.92% | 31.03% |
| 2019 | 3.58% | 5.94% | 2.75% | -9.80% | -0.38% | -4.44% | -1.66% | 4.27% | -1.01% | 1.90% | 3.58% | 12.00% | 16.14% |
| 2018 | -3.56% | -4.74% | 0.45% | 4.78% | 5.62% | 0.34% | 15.80% | 7.51% | 1.57% | 1.05% | 9.96% | -2.46% | 40.45% |
| 2017 | 4.73% | 8.23% | 1.57% | -2.44% | -2.41% | 3.43% | 0.44% | -1.03% | 5.23% | -4.21% | 3.95% | -0.21% | 17.83% |
| 2016 | -6.12% | -8.34% | 0.01% | 4.89% | 0.00% | 4.96% | 5.26% | -5.60% | 3.23% | -8.00% | -8.51% | 9.58% | -10.37% |
| 2015 | 4.36% | -1.85% | 3.53% | -1.07% | 10.54% | 5.82% | 1.22% | -1.97% | 1.63% | -2.53% | 1.21% | 2.71% | 25.39% |
| 2014 | 5.90% | 11.37% | -1.26% | 0.41% | 2.13% | 3.86% | -1.79% | 4.93% | 2.03% | 2.28% | 3.44% | 1.28% | 39.75% |
| 2013 | 8.86% | 2.74% | 3.90% | -2.48% | -3.17% | -7.60% | 8.12% | -2.33% | -2.08% | -1.01% | 1.80% | 1.55% | 7.29% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of LLY is 69, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Eli Lilly and Company (LLY) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Eli Lilly and Company provided a 0.70% dividend yield over the last twelve months, with an annual payout of $5.20 per share. The company has been increasing its dividends for 45 consecutive years, earning it the status of a dividend aristocrat.
| Period | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $5.20 | $4.52 | $3.92 | $3.40 | $2.96 | $2.58 | $2.25 | $2.08 | $2.04 | $2.00 | $1.96 | $1.96 |
Dividend yield | 0.70% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.95% | 2.46% | 2.77% | 2.37% | 2.84% | 3.84% |
Monthly Dividends
The table displays the monthly dividend distributions for Eli Lilly and Company. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | $0.00 | $1.30 | $0.00 | $0.00 | $1.30 | $0.00 | $0.00 | $1.30 | $0.00 | $0.00 | $1.30 | $5.20 | |
| 2023 | $0.00 | $1.13 | $0.00 | $0.00 | $1.13 | $0.00 | $0.00 | $1.13 | $0.00 | $0.00 | $1.13 | $0.00 | $4.52 |
| 2022 | $0.00 | $0.98 | $0.00 | $0.00 | $0.98 | $0.00 | $0.00 | $0.98 | $0.00 | $0.00 | $0.98 | $0.00 | $3.92 |
| 2021 | $0.00 | $0.85 | $0.00 | $0.00 | $0.85 | $0.00 | $0.00 | $0.85 | $0.00 | $0.00 | $0.85 | $0.00 | $3.40 |
| 2020 | $0.00 | $0.74 | $0.00 | $0.00 | $0.74 | $0.00 | $0.00 | $0.74 | $0.00 | $0.00 | $0.74 | $0.00 | $2.96 |
| 2019 | $0.00 | $0.65 | $0.00 | $0.00 | $0.65 | $0.00 | $0.00 | $0.65 | $0.00 | $0.00 | $0.65 | $0.00 | $2.58 |
| 2018 | $0.00 | $0.56 | $0.00 | $0.00 | $0.56 | $0.00 | $0.00 | $0.56 | $0.00 | $0.00 | $0.56 | $0.00 | $2.25 |
| 2017 | $0.00 | $0.52 | $0.00 | $0.00 | $0.52 | $0.00 | $0.00 | $0.52 | $0.00 | $0.00 | $0.52 | $0.00 | $2.08 |
| 2016 | $0.00 | $0.51 | $0.00 | $0.00 | $0.51 | $0.00 | $0.00 | $0.51 | $0.00 | $0.00 | $0.51 | $0.00 | $2.04 |
| 2015 | $0.00 | $0.50 | $0.00 | $0.00 | $0.50 | $0.00 | $0.00 | $0.50 | $0.00 | $0.00 | $0.50 | $0.00 | $2.00 |
| 2014 | $0.00 | $0.49 | $0.00 | $0.00 | $0.49 | $0.00 | $0.00 | $0.49 | $0.00 | $0.00 | $0.49 | $0.00 | $1.96 |
| 2013 | $0.49 | $0.00 | $0.00 | $0.49 | $0.00 | $0.00 | $0.49 | $0.00 | $0.00 | $0.49 | $0.00 | $1.96 |
Dividend Yield & Payout
Dividend Yield
Payout Ratio
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Eli Lilly and Company. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Eli Lilly and Company was 68.27%, occurring on Mar 5, 2009. Recovery took 1428 trading sessions.
The current Eli Lilly and Company drawdown is 21.95%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -68.27% | Aug 9, 2000 | 2154 | Mar 5, 2009 | 1428 | Nov 4, 2014 | 3582 |
| -46.39% | Jan 10, 1992 | 404 | Aug 13, 1993 | 408 | Mar 27, 1995 | 812 |
| -43.28% | Mar 8, 1999 | 254 | Mar 7, 2000 | 80 | Jun 29, 2000 | 334 |
| -40.74% | Sep 15, 1987 | 25 | Oct 19, 1987 | 353 | Mar 13, 1989 | 378 |
| -30.29% | Apr 21, 1981 | 111 | Sep 25, 1981 | 331 | Jan 17, 1983 | 442 |
Volatility
Volatility Chart
The current Eli Lilly and Company volatility is 11.79%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Valuation
The Valuation section provides an assessment of the market value of Eli Lilly and Company compared to its peers in the Drug Manufacturers - General industry.
PE Ratio
The chart displays the price to earnings (P/E) ratio for LLY in comparison to other companies of the Drug Manufacturers - General industry. Currently, LLY has a PE value of 78.7. This PE ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.PEG Ratio
The chart displays the price to earnings to growth (PEG) ratio for LLY in comparison to other companies of the Drug Manufacturers - General industry. Currently, LLY has a PEG value of 0.7. This PEG ratio falls in the average range for the industry.Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Eli Lilly and Company.
Loading data...
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |